Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
Status:
Enrolling by invitation
Trial end date:
2022-06-19
Target enrollment:
Participant gender:
Summary
This study analyzes the affects or Adderall extended-release (XR) in Subjects receiving brain
stimulation therapy for the treatment of Major Depressive Disorder. Subjects will be assigned
by chance to active or placebo group. Active group will be asked to take one 15 mg pill once
daily of Adderall XR (amphetamine) and the Placebo group will be asked take an identical
appearing tablet/capsule, one tablet by mouth daily. The placebo tablet has no active
ingredients and has no affect on the body or mind. With the exception of the study drug, all
other study activities between both groups will be identical. Subjects will use the assigned
study drug two weeks before therapy and throughout the first 10 therapy treatments. A total
of seven(7) visits will be required for screening, drug assignment, and completion of mood
assessments. This study will enroll a total of 30 Subjects.